SWS Partners’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.36M | Sell |
13,364
-109,638
| -89% | -$23.6M | 0.73% | 44 |
|
|
2026
Q1 | $2.68M | Buy |
123,002
+111,185
| +941% | +$24.7M | 0.66% | 54 |
|
|
2025
Q4 | $2.7M | Sell |
11,817
-1,180
| -9% | -$269K | 0.65% | 55 |
|
|
2025
Q3 | $3.01M | Buy |
12,997
+420
| +3% | +$85.5K | 0.73% | 48 |
|
|
2025
Q2 | $2.33M | Sell |
12,577
-2,194
| -15% | -$408K | 0.63% | 56 |
|
|
2025
Q1 | $3.09M | Buy |
14,771
+327
| +2% | +$63.6K | 1.02% | 30 |
|
|
2024
Q4 | $2.57M | Sell |
14,444
-35
| -0.2% | -$6.43K | 0.78% | 48 |
|
|
2024
Q3 | $2.86M | Sell |
14,479
-2,123
| -13% | -$396K | 0.91% | 32 |
|
|
2024
Q2 | $2.84M | Buy |
16,602
+356
| +2% | +$59K | 0.85% | 38 |
|
|
2024
Q1 | $2.96M | Sell |
16,246
-824
| -5% | -$142K | 0.88% | 39 |
|
|
2023
Q4 | $2.65M | Sell |
17,070
-318
| -2% | -$46.4K | 0.86% | 41 |
|
|
2023
Q3 | $2.59M | Sell |
17,388
-2,664
| -13% | -$391K | 0.96% | 39 |
|
|
2023
Q2 | $2.7M | Buy |
20,052
+2,815
| +16% | +$413K | 0.97% | 37 |
|
|
2023
Q1 | $2.75M | Sell |
17,237
-648
| -4% | -$99.1K | 1.02% | 28 |
|
|
2022
Q4 | $2.89M | Buy |
17,885
+1,359
| +8% | +$208K | 1.37% | 21 |
|
|
2022
Q3 | $2.22M | Buy |
16,526
+161
| +1% | +$23.1K | 1.03% | 36 |
|
|
2022
Q2 | $2.51M | Sell |
16,365
-2,028
| -11% | -$310K | 2.11% | 8 |
|
|
2022
Q1 | $2.98M | Sell |
18,393
-2,008
| -10% | -$292K | 1.95% | 11 |
|
|
2021
Q4 | $2.76M | Sell |
20,401
-978
| -5% | -$116K | 1.57% | 20 |
|
|
2021
Q3 | $2.31M | Sell |
21,379
-12,430
| -37% | -$1.42M | 1.43% | 23 |
|
|
2021
Q2 | $3.81M | Buy |
33,809
+2,160
| +7% | +$243K | 2.48% | 5 |
|
|
2021
Q1 | $3.42M | Buy |
31,649
+3,832
| +14% | +$410K | 2.36% | 6 |
|
|
2020
Q4 | $2.98M | Buy |
27,817
+790
| +3% | +$75.9K | 1.33% | 16 |
|
|
2020
Q3 | $2.37M | Buy |
27,027
+9,932
| +58% | +$935K | 1.19% | 25 |
|
|
2020
Q2 | $1.62M | Sell |
17,095
-2,822
| -14% | -$248K | 2.07% | 9 |
|
|
2020
Q1 | $1.52M | Buy |
+19,917
| New | +$1.7M | 1.09% | 24 |
|
|
2018
Q4 | $1.84M | Sell |
19,934
-7,179
| -26% | -$631K | 1.39% | 21 |
|
|
2018
Q3 | $2.56M | Buy |
27,113
+5,588
| +26% | +$530K | 1.63% | 23 |
|
|
2018
Q2 | $1.99M | Buy |
21,525
+2,658
| +14% | +$260K | 1.4% | 27 |
|
|
2018
Q1 | $1.73M | Buy |
18,867
+295
| +2% | +$32.4K | 1.27% | 24 |
|
|
2017
Q4 | $1.8M | Buy |
+18,572
| New | +$1.75M | 1.35% | 23 |
|
Other funds holding ABBV
SWS Partners's ABBV Position: Q2 2026 in Review
SWS Partners reduced its AbbVie (ABBV) stake by 89% in Q2 2026, selling an estimated $23.6M and leaving 13,364 shares worth $3.36M. The position accounts for 0.73% of the portfolio, ranked #44.
SWS Partners first reported a position in ABBV in Q4 2017 and has held it in 31 quarters since. The position peaked at $3.81M in Q2 2021. 4,227 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- SWS Partners held 13,364 shares of AbbVie worth $3.36M as of Q2 2026.
- SWS Partners sold 109,638 AbbVie shares in Q2 2026, an estimated $23.6M.
- AbbVie made up 0.73% of SWS Partners's portfolio in Q2 2026, its #44 holding.
- SWS Partners first reported a position in AbbVie in Q4 2017 and has held it in 31 quarters since.
- SWS Partners's AbbVie position peaked at $3.81M in Q2 2021.
- 4,227 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on SWS Partners's 13F filing for Q2 2026, filed 3 Aug 2026.